U.S. Markets close in 1 hr 45 mins

ArQule enrolls first patient in Phase 3 trial for carcinoma candidate tivantinib

ArQule and Daiichi Sankyo Company announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC trial of tivantinib, an investigational selective inhibitor of MET, a receptor tyrosine kinase, which is being evaluated for the treatment of patients diagnosed with hepatocellular carcinoma who have received one or two prior systemic anti-cancer therapies. The METIV-HCC trial is a controlled study of previously treated patients with MET-high inoperable HCC who will receive tivantinib or placebo. The primary endpoint is overall survival, and the secondary endpoint is progression-free survival. Approximately 300 patients are planned to be enrolled.